Profil
Andreas Seidl currently works at Formycon AG, as Chief Scientific Officer from 2022.
Dr. Seidl also formerly worked at LEUKOCARE AG, as Chief Operating Officer from 2019 to 2022, Hexal Biotech GmbH, as Head-Analytics & Quality Control from 2002 to 2010, and Novartis AG, as Site Manager from 2010 to 2015.
Dr. Seidl received his doctorate degree from Universität Konstanz.
Postes actifs de Andreas Seidl
| Sociétés | Poste | Début |
|---|---|---|
| FORMYCON AG | Directeur Technique/Scientifique/R&D | 01/07/2022 |
Anciens postes connus de Andreas Seidl
| Sociétés | Poste | Fin |
|---|---|---|
LEUKOCARE AG
LEUKOCARE AG Medical/Nursing ServicesHealth Services Develops protein stabilization and protection solutions | Directeur des opérations | 01/01/2022 |
| NOVARTIS AG | Corporate Officer/Principal | 01/01/2015 |
Formation de Andreas Seidl
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Novartis AG
Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Universität Konstanz
Universität Konstanz Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LEUKOCARE AG
LEUKOCARE AG Medical/Nursing ServicesHealth Services Develops protein stabilization and protection solutions | Health Services |
Formycon AG
Formycon AG Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
















